COVID-19 | Verdi

Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies

2023

Authors: Rouzine IM, Rozhnova G.

Published in: Nature Communications Medicine

Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis

2023

Authors: Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, D’Andrea V, Trentini F, Ajelli M, Poletti P, Merler S.

Published in: JAMA Network Open

Clinical Presentation and Outcome of Acute Respiratory Illnesses in South African Children During the COVID-19 Pandemic

2023

Authors: Redfern A, van der Zalm MM, Lishman J, Goussard P, Smit L, Dagan R, Barday M, Mare M, Claassen M, Van Zyl G, Rabie H, Verhagen LM.

Published in: The Pediatric Infectious Disease Journal

The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts

2023

Authors: Westerhof I, de Hoog M, Ieven M, Lammens C, van Beek J, Rozhnova G, Eggink D, Euser S, Wildenbeest J, Duijts L, van Houten M, Goossens H, Giaquinto C, Bruijning‑Verhagen P.

Presented at: ESPID 2023

View poster

Ethnic group differences in rates of SARS-CoV-2 testing, PCR-confirmed infections and COVID-19 related hospital admissions in young children by SARS-CoV-2- variant: national birth cohort study

2023

Authors: Abdullahi F, Hardelid P, Nguyen V, Thorne C, Linda Wijlaar.

Presented at: ESPID 2023

View poster

Clinical presentation and outcome of acute respiratory illnesses in South African children during the COVID-19 pandemic

2023

Authors: Redfern A, van der Zalm MM, Lishman J, Goussard P, Smit L, Dagan R, Barday MM, Mare M, Claassen M, Van Zyl G, Rabie H, Verhagen LM.

Presented at: ESPID 2023

View poster

Clinical features of SARS-CoV-2 infection in children and adolescents who experienced COVID-19 across Parental, Delta, and Omicron waves in Italy: a prospective observational study

2023

Authors: Di Chiara C, Boracchini R, Sturniolo G, Barbieri A, Costenaro P, De Pieri M, Liberati C, Zin A, Cozzani S, Padoan A, Bonfante F, Kakkar F, Cantarutti A, Donà D, Giaquinto C.

Presented at: ESPID 2023

View poster

Hybrid immunity upon mRNA vaccines induce a stronger and durable SARS-CoV-2 immune response in children

2023

Authors: Di Chiara C, Cantarutti A, Petrara MR, Bonfante F, Cosma C, Carmona F, Pagliari M, Cotugno N, Boracchini R, Meneghel A, Benetti E, Bosa L, Palma P, De Rossi A, Giaquinto C, Donà D, Padoan A, and the VERDI/ORCHESTRA study teams.

Presented at: ESPID 2023

View poster

Participatory Surveillance for COVID-19 Trend Detection in Brazil: Cross-sectional Study

2023

Authors: Wittwer S, Paolotti D, Lichand G, Leal Neto O.

Published in: JMIR Public Health and Surveillance

EU tasks VERDI Consortium with investigating mpox and improving pandemic preparedness

2023

The VERDI Consortium, coordinated by the University of Padua and Fondazione Penta ETS (Italy), has received an additional €5 million funding from the European Union (EU). Thanks to this contribution, VERDI will examine the impact of mpox on populations at higher risk of infection or severe disease, such as people with HIV, pregnant women and children. 

Padova, Italy – 30 March 2023 

Between the onset of the mpox outbreak in May 2022 and the end of the same year, more than 82,000 cases of mpox were reported across the globe. Of the 110 countries with confirmed mpox cases, 103 were relatively new to the spread of the virus, making the situation unprecedented. The monkeypox pandemic has put additional pressure on healthcare systems that were already strained by three years of COVID-19; it has also reinforced the need to be prepared for emerging and re-emerging infectious diseases. 

With a view to better understanding and responding to the mpox outbreak, the European Union has granted VERDI a top-up funding of €5 million to embed mpox-related research into the existing project. Established in 2021, VERDI puts together researchers from around the world to collaboratively study the potential impact of new SARS-CoV-2 variants of concern in pregnant women and children. 

As with SARS-CoV-2 and its variants, the future development of the mpox public health emergency is uncertain. Thus, vigilance is needed to monitor the epidemiology of mpox in populations at higher risk of infection, such as people living with HIV, as well as other groups who may be at higher risk of severe disease, such as pregnant women and children. 

We must be proactive in our approach to pandemics, especially considering the potential emergence of dangerous pathogens and viruses driven by climate change. VERDI’s new focus on pandemic preparedness, including COVID-19 and mpox, will ensure that we are ready to address the challenges of future outbreaks”, said Carlo Giaquinto, President of Fondazione Penta ETS and VERDI Scientific Coordinator. 

The EU contribution will support the development of a research infrastructure for pandemic preparedness across VERDI’s three populations of interest, namely pregnant women, children, and adults with sexually transmitted infections. Thanks to the wealth of regional and international cohorts involved in VERDI and the diverse and complementary expertise of its members, the VERDI network will be able to rapidly pivot towards research on emerging infections. Furthermore, it will provide recommendations for management of future emerging and re-emerging pathogens on a global scale. 

We are delighted to have this opportunity to broaden the focus of VERDI and include mpox and preparedness, and all partners in the Consortium are excited about strengthening our ability to respond to new public health threats in a timely way”, commented Ali Judd, Professor of Epidemiology at University College London, member of the Penta ID Network and VERDI Scientific Coordinator. 

Additionally, the focus of the Cohorts Coordination Board (CCB), which so far has been COVID-19, will be expanded to include existing networks and relevant patient groups on mpox and sexually transmitted infections. Evelina Tacconelli, Professor of Infectious Diseases at the University of Verona (Italy) and coordinator of the CCB, said: “Strengthening synergies and information-sharing among countries is of utmost importance to prepare health systems to effectively respond to outbreaks of infectious diseases. By opening the CCB to mpox and sexually transmitted infections, we can ensure that these vulnerable populations are involved in research aimed at enhancing our society’s preparedness to handle future pandemics.

The expertise and research tools for outbreak preparedness generated from the project will ensure that VERDI has a long-lasting impact on global pandemic preparedness, in order to make sure our societies are better equipped to handle future outbreaks. 

Read the press release in English and Italian

Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa

2023

Authors: Davies MA, Morden E, Rousseau P, Arendse J, Bam JL, Boloko L, Cloete K, Cohen C, Chetty N, Dane P, Heekes A, Hsiao NY, Hunter M, Hussey H, Jacobs T, Jassat W, Kariem S, Kassanjee R, Laenen I, Roux SL, Lessells R, Mahomed H, Maughan D, Meintjes G, Mendelson M, Mnguni A, Moodley M, Murie K, Naude J, Ntusi NAB, Paleker M, Parker A, Pienaar D, Preiser W, Prozesky H, Raubenheimer P, Rossouw L, Schrueder N, Smith B, Smith M, Solomon W, Symons G, Taljaard J, Wasserman S, Wilkinson RJ, Wolmarans M, Wolter N, Boulle A.

Published in: International Journal of Infectious Diseases

mRNA vaccines induce a higher antibodies response in children with previous COVID-19

2023

Authors: Di Chiara C, Cantarutti A, Bonfante F, Petrara MR, Cosma C, Pagliari M, Cotugno N, Meneghel A, Benetti E, Bosa L, Palma P, De Rossi A, Giaquinto C, Donà D, Padoan A, for the VERDI study team.

Presented at: CROI 2023

Read more

Management of Mpox in people with HIV attending a sexual health department in London, UK

2023

Authors: Girometti N, Burton F, Spencer M, Agunbiade S, Byrne R, Bracchi M, Jones R, Dwyer E, Whitlock GG, Tittle V, Pozniak AL, Boffito M

Presented at: CROI 2023

Read more

Pediatric coronavirus disease 2019 in Africa

2023

Authors: Van der Zalm MM, Donà D, Rabie H.

Published in: Current Opinions in Pediatrics

Evaluating COVID-19 vaccine allocation policies using Bayesian m-top exploration

2023

Authors: Cimpean A, Verstraeten T, Willem L, Hens N, Nowé A, Libin P.

Published in: medRxiv (preprint), January 2023

Mid- and Long-Term Atrio-Ventricular Functional Changes in Children after Recovery from COVID-19

2023

Authors: Sabatino J, Di Chiara C, Di Candia A, Sirico D, Donà D, Fumanelli J, Basso A, Pogacnik P, Cuppini E, Romano LR, Castaldi B, Reffo E, Cerutti A, Biffanti R, Cozzani S, Giaquinto C, Di Salvo G.

Published in: Journal of Clinical Medicine

Early Treatments of Fragile Children with COVID-19—Results of CLEVER (Children COVID Early Treatment), a Retrospective, Observational Study

2023

Authors: Minotti C, Mengato D, De Pieri M, Trivellato S, Francavilla A, Di Chiara C, Liberati C, Mattera R, Biffi A, Giaquinto C, Venturini F, Donà D.

Published in: Viruses

Attitudes towards booster, testing and isolation, and their impact on COVID-19 response in winter 2022/2023 in France, Belgium, and Italy: a cross-sectional survey and modelling study

2023

Authors: De Meijere G, Valdano E, Castellano C, Debin M, Kengne-Kuetche C, Turbelin C, Noël H, Weitz J, Paolotti D, Hermans L, Hens N, Colizza V.

Published in: The Lancet Regional Health – Europe

The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts

2022

Authors: Westerhof I, de Hoog M, Ieven M, Lammens C, van Beek J, Rozhnova G, Eggink D, Euser S, Wildenbeest J, Duijts L, van Houten M, Goossens H, Giaquinto C, Bruijning-Verhagen P.

Published in: International Journal of Infectious Diseases

COVID-19 in Infants Less than 3 Months: Severe or Not Severe Disease?

2022

Authors: Donà D, Montagnani C, Di Chiara C, Venturini E, Galli L, Lo Vecchio A, Denina M, Olivini N, Bruzzese E, Campana A, Giacchero R, Salvini F, Meini A, Ponzoni M, Trapani S, Rossi E, Lombardi MH, Badolato R, Pierri L, Pruccoli G, Rossin S, Colomba C, Cazzato S, Pacati I, Nicolini G, Pierantoni L, Bianchini S, Krzysztofiak A, Garazzino S, Giaquinto C, Castelli Gattinara G

Published in: Viruses

Symptom presentation among SARS-CoV-2 positive cases and the impact of COVID-19 vaccination; three prospective household cohorts

2022

Authors: Westerhof I, de Hoog M, Ieven M, Lammens C, van Beek J, Rozhnova G, Eggink D, Euser S, Wildenbeest J, Duijts L, van Houten M, Goossens H, Giaquinto C, Bruijning-Verhagen P.

Published in: medRxiv (preprint)

Controlling SARS-CoV-2 in schools using repetitive testing strategies

2022

Authors: Torneri A, Willem L, Colizza V, Kremer C, Meuris C, Darcis G, Hens N, Libin PJK.

Published in: eLife

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

2022

Authors: Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, Giaquinto C, Judd A, Leibovici L, Hernán MA, Lipsitch M, Reis BY, Balicer RD, Dagan N.

Published in: The New England Journal of Medicine

Seasonal patterns of SARS-CoV-2 transmission in secondary schools: a modelling study

2022

Authors: Pham TM, Westerhof I, Bootsma MCJ, Kretzschmar ME, Rozhnova G, Bruijning-Verhagen P.

Published in: MedRxiv

Omicron Neutralizing and Anti-SARS-CoV-2 S-RBD Antibodies in Naïve and Convalescent Populations After Homologous and Heterologous Boosting With an mRNA Vaccine

2022

Authors: Pagliari M, Mazzetto E, Gastaldelli M, Bortolami A, Donà D, Padoan A, Di Chiara C, Pezzani MD, Cosma C, Napolitan A, Quaranta EG, Giussani E, Fusaro A, Pascarella M, Aita A, Liberati C, Lorusso A, Monne I, De Rossi A, Basso D, Porru S, Ricci A, Terregino C, Plebani M, Tacconelli E*, Giaquinto C*, Bonfante F*.

Published in: Lancet Preprints

Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis

2022

Authors: Hussey H, Davies MA, Heekes A, Williamson C, Valley-Omar Z, Hardie D, Korsman S, Doolabh D, Preiser W, Maponga T, Iranzadeh A, Wasserman S, Boloko L, Symons G, Raubenheimer P, Parker A, Schrueder N, Solomon W, Rousseau P, Wolter N, Jassat W, Cohen C, Lessells R, Wilkinson RJ, Boulle A, Hsiao NY.

Published in: International Journal of Infectious Diseases

Editorial: Modelling COVID-19 in school settings to evaluate prevention and control protocols

2022

Authors: Colosi E, Bassignana G, Barrat A, Colizza V.

Published in: Anaesthesia Critical Care & Pain Medicine

Early Use of Sotrovimab in Children:A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2

2022

Authors: Di Chiara C, Mengato D, De Pieri M, Longo G, Benetti E, Venturini F, Giaquinto C and Donà D.

Published in: Children

123